Oculus Innovative Sciences Announces Received 'Strong Consensus' Rating for Use With Kinetic Concepts' Negative Pressure Wound Therapy With Instillation

Oculus Innovative Sciences, Inc.

, a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries, today announced that the company's Microcyn® Negative-Pressure Wound Therapy Solution™ received a "strong consensus" rating for use with Kinetic Concepts Inc.'s (KCI) Negative Pressure Wound Therapy with Instillation (NPWTi) as identified in the First International Consensus Guidelines. The guidelines were published in the December 2013 issue of Journal of Plastic and Reconstructive Surgery. In addition to Microcyn, only one other irrigation solution available in the United States also received strong consensus (greater than 80% agreement of the panel) for use with NPWTi. That product is a broad-spectrum, polynexanide-based antimicrobial solution.    Other solutions reviewed, including acetic acid, sodium hypochlorite, silver nitrate and saline, did not achieve the panel support necessary for a "strong consensus" rating from the group.  The international consensus panel, convened by MedStar Georgetown University Hospital (through an unrestricted educational grant from KCI), provides the first authoritative guidance on the appropriate use of NPWTi. The guidelines include nine major consensus statements that provide clinical guidance in the following areas: * Appropriate wound types that would benefit from instillation therapy * Importance of debridement for acutely infected, chronically infected, or contaminated wounds * Appropriate instillation solutions, volume of solution and soak time * Appropriate pressure settings and modes * Optimal duration of NPWTi "We're honored that Microcyn's safety and efficacy in a negative pressure wound therapy setting has generated such overwhelming support from a truly premiere slate of healthcare professionals," said Dr. Robery Northey, Oculus' vice president of research and development. "Our research and development team continues to work diligently to create a variety of Microcyn-based solutions that are safe and compatible in a broad array of indications and devices, including negative pressure instillation."